Glucose Monitoring During Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

22 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-31

Study Completion Date

2022-08-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a research study to look at blood sugar changes during chemotherapy using a continuous blood sugar monitoring device. The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course. Each patch lasts for about 2-weeks. During chemotherapy visits, new patches will be placed and will be worn until the chemotherapy course is complete. Participants will be in this study for 6 months. Approximately 50 patients will be enrolled in this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glucose Monitoring to Predict and Treat High Glucose Levels After Steroid Treatment

NCT04210128

Breast Cancer Pancreatic Cancer Diabetes +1 more

COMPLETED

Continuous Glucose Monitor Application After Hospital Discharge for the Improvement of Outcomes in Patients With Poorly Controlled Type 2 Diabetes and Active Cancer

NCT04938869

Hematopoietic and Lymphoid System Neoplasm Malignant Solid Neoplasm Type 2 Diabetes Mellitus

COMPLETED NA

Study on Glycemic Variations in Diabetic Patients Treated With Chemotherapy: Benefit of Continuous Interstitial Glucose Measurement

NCT04315857

Diabetes Chemotherapy Interstitial Glycemia +1 more

COMPLETED

Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge

NCT04417270

Diabetes Mellitus

COMPLETED NA

Postpartum Continuous Glucose Monitoring (CGM) Study

NCT05714761

Gestational Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective observational cohort study monitoring trends in glucose in patients with early stage breast cancer treated with neoadjuvant or adjuvant chemotherapy. Patients will wear a noninvasive glucose monitoring sensor, the Freestyle Libre Pro for the duration of chemotherapy. The primary goal of this trial is to evaluate the prevalence of hyperglycemia in patients with early-stage breast cancer during neoadjuvant/adjuvant chemotherapy. Fifty patients will be enrolled. During each chemotherapy encounter, subjects will have their glucose sensor scanned in order to download subjects' glucose data. If the sensor has become no longer adherent to the participant's skin, participants will bring the sensor with them to the chemotherapy infusion center to be scanned. During each chemotherapy encounter, the Free Style Libre sensor will be replaced by the study team. Participants who receive chemotherapy every three weeks will be asked to come in 10-14 days after their chemotherapy infusion to replace the sensor. The sensors will be worn through completion of chemotherapy (the duration will vary based on the individual's chemotherapy regimen). Patients will have fructosamine, a glucose biomarker, and serum creatinine testing at baseline and every 3 weeks (weeks 3, 6, 9, 12, 15, 18, 21, 24) until week 24 (note: week 15, 18, and 21 are optional). Patients will have additional glucose biomarker testing (hemoglobin a1c, glucose, and insulin \[fasting preferred\]) at baseline, week 12 and week 24. Patients will also complete questionnaires assessing for symptoms of chemotherapy induced peripheral neuropathy, quality of life, and fatigue at baseline, week 12 and week 24. Visits will be conducted within the below specified windows forbidding unexpected circumstances such as missed appointments or loss to follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Hyperglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FreeStyle Libre sensor cohort

Patients with early stage breast cancer will have their blood glucose levels monitored by the Freestyle libre pro sensor.

FreeStyle Libre Pro

Intervention Type DEVICE

The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FreeStyle Libre Pro

The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* History of stage I-III breast cancer
* Patient scheduled to receive adjuvant or neoadjuvant chemotherapy
* Signed informed consent

Exclusion Criteria

* Current treatment with insulin
* Current treatment with non-topical steroids, with the exception of steroid treatment as a supportive chemotherapy medication
* Inability to provide informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No